Abstract:Uterine serous carcinoma (USC) is a biologically aggressive subtype of endometrial cancer with a high recurrence rate and poor prognosis disproportionately affecting black women. Whole-exome-sequencing analysis revealed that up to 10% of USC harbor features of ultra/hypermutation due to a deficiency of polymerase e (POLE) and/or mismatched-repair genes (MMRd). These tumors are notable for having a high number of single nucleotide variants (SNV), no LOH segments or copy-number variants (CNV) and a peculiar genetic signature characterized by an increased rate of C > A transversions. In contrast, the overwhelming majority of USC (~ 90%) are POLE/MMR proficient, have a low number of SNV and demonstrate alteration in genes including TP53, PIK3CA mutation/amplification, ERBB2 amplification, CCNE1 amplification, FBXW7 mutation/deletion, PPP2R1A mutation, and somatic mutations involving homologous recombination genes. Frequent mutations in CHD4/Mi2b, a member of the NuRD-chromatin-remodeling-complex, and TAF1, an element of the core TFIID transcriptional machinery are also detected in a significant number of USC. Somatic CNVs, a sign of genomic instability, are identified in the majority of USC with multiple copy number gains and copy number losses, with the most frequent events taking place in pathways similar to those found from analysis of SNVs. In addition to loss of TP53, frequent deletion of a small segment of chromosome 19 containing MBD3, a member of the NuRD-chromatin-modification-complex, and frequent amplification of chromosome segments containing PIK3CA, ERBB2 (encoding for the HER2/neu receptor) and CCNE1 (a target of FBXW7-mediated ubiquitination) are commonly detected. Overall, these findings suggest that both somatic point mutations (SNV) and somatic CNV play a major role in the pathogenesis of USC. Importantly, the frequent mutation of DNA damage, chromatin remodeling, cell cycle and cell proliferation pathways in USC including the overexpression/amplification of HER2/neu, CCNE1 and the tumor-associated calcium signal transducer 2 (TACSTD2/TROP2) genes, suggest novel targets for therapy against this lethal variant of endometrial cancer. Citation Format: Alessandro D. Santin. Molecular diversity of uterine serous carcinoma [abstract]. In: Proceedings of the AACR Special Conference on Endometrial Cancer: Transforming Care through Science; 2023 Nov 16-18; Boston, Massachusetts. Philadelphia (PA): AACR; Clin Cancer Res 2024;30(5_Suppl) nr IA016.

Molecular Analysis of Mixed Endometrioid and Serous Adenocarcinoma of the Endometrium

Cdna Microarray Analysis and Immunohistochemistry Reveal a Distinct Molecular Phenotype in Serous Endometrial Cancer Compared to Endometrioid Endometrial Cancer

Identification of Distinct Molecular Subtypes of Endometrioid Adenocarcinoma

Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma

Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer

Molecular characterization of adenocarcinoma and squamous carcinoma of the uterine cervix using microarray analysis of gene expression

Molecular Classification Outperforms Histologic Classification in Prognostication of High-grade Endometrial Carcinomas With Undifferentiated and Sarcomatous Components

Lymph node metastases in endometrial carcinoma: A modern assessment in the era of sentinel lymph node mapping and molecular subtyping

Molecular characterization of endometrial cancer and therapeutic implications

Molecular Classification of Endometrial Cancers Using an Integrative DNA Sequencing Panel

Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray

Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma

Abstract IA016: Molecular diversity of uterine serous carcinoma

Molecular classification of metastatic and recurrent endometrial endometrioid carcinoma: prognostic relevance among low‐ and high‐stage tumours

Molecular Classification of Endometrial Cancer of Chinese Population.

Molecular Subtypes Identified by Gene Expression Profiling in Early Stage Endometrioid Endometrial Adenocarcinoma

Integrative Analysis of Genomic and Epigenetic Regulation of Endometrial Cancer

Association of a novel endometrial cancer biomarker panel with prognostic risk, platinum insensitivity, and targetable therapeutic options

Molecular characterization in the prediction of disease extent in endometrial carcinoma

Molecular classification of endometrial carcinoma applied to endometrial biopsy specimens: Towards early personalized patient management

Clinicopathologic and molecular genetic comparison of primary uterine serous adenocarcinomas from African American and Caucasian women.